3 October 2024 F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic.
Cambridge, UK-based drug discovery and development company Mission Therapeutics today announced the publication of a peer-reviewed article titled ‘Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson’s disease (PD)’ in the journal Nature Communications. 13 November 2023
UK-based Barinthus Biotherapeutics today presented data from two hepatitis B virus (HBV) clinical trials at The American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting 2023. 10 November 2023
The US Food and Drug Administration yesterday approved Japanese pharma major Takeda’s Adzynma (ADAMTS13, recombinant-krhn; TAK-755), adding to the approval a day earlier of the firm’s bowel cancer drug Fruzaqla (fruquintinib). 10 November 2023
Belgium’s largest pharma company, UCB, has announced new long-term data from the Bimzelx (bimekizumab) Phase IIb study BE AGILE and its open label extension (OLE). 10 November 2023
The US Food and Drug Administration (FDA) has approved Ixchiq, French specialty vaccines developer Valneva’s single-dose, live-attenuated vaccine indicated for the prevention of disease caused by chikungunya virus. 10 November 2023
UK oncology-focussed biotech ValiRx edged up 2.5% to 12.30 pence this morning, after it announced it has entered into an agreement with StingRay Bio to investigate a lead series of drug candidates for use in oncology. 10 November 2023
A Phase II failure for Californian cell therapy company Atara Biotherapeutics has prompted a share sell-off, with the company’s stock falling 80% in value on Thursday. 10 November 2023
Cells are the basic unit of life and are themselves living. They coordinate, construct, kill, and multiply. Using human cells as medicines is as intuitively thrilling as it is technically difficult. 9 November 2023
WuXi XDC has published a prospectus for its upcoming initial public offering (IPO), detailing plans to raise $470 million with a listing on the Hong Kong Stock Exchange. 9 November 2023
The UK's National Institute for Health and Care Excellence (NICE) has recommended Lamzede (velmanase alfa) in its final evaluation document as an option for treating the non-neurological signs and symptoms of mild to moderate alpha-mannosidosis in England and Wales. 9 November 2023
The market for myasthenia gravis (MG), an autoimmune and neuromuscular disease characterized by muscle weakness and fatigue, is set to experience a compound annual growth rate (CAGR) of 8.3% across the seven major markets. 9 November 2023
Britain’s biggest drugmaker AstraZeneca has exceeded revenues expectations handily in the third quarter 2023, with robust demand in oncology leading the way. 9 November 2023
US biotech major Biogen today reported third quarter 2023 results and updated full year 2023 guidance that failed to impress investors, with its shares falling 4.7% to $235.34 in early trading’ 8 November 2023
Californian drugmaker Gilead Sciences has exceeded estimates in the third quarter, with revenues of around $7.1 billion and earnings per share (EPS) of $1.73. 8 November 2023
Danish drugmaker Genmab has reported third quarter 2023 revenues of 4.7 billion Danish kroner ($420 million), better than the 4.5 billion kroner expected according to the FT consensus forecast. 8 November 2023
South Korea’s Chong Kun Dang Pharmaceutical's stock soared 26.1% to end at 128,000 won on Monday, on news of a deal with Swiss pharma giant Novartis. 7 November 2023
A biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer, is to go by a new name. 7 November 2023
Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to expand its portfolio of marketed rare disease medicines. 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Bristol Myers Squibb has received a new approval from the US Food and Drug Administration for its blockbuster checkpoint blocker, Opdivo (nivolumab). 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
The US Food and Drug Administration (FDA) has granted the Gilead Sciences subsidiary Kite a Regenerative Medicine Advanced Therapy Designation (RMAT) for Yescarta (axicabtagene ciloleucel) for adults with newly-diagnosed, high-risk large B-cell lymphoma (LBCL). 3 October 2024
Kedrion Biopharma has finalized an agreement with Germany-based Biotest for the long-term commercialization and distribution of Yimmugo (immune globulin) in the USA. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Privately-held Ferring Pharmaceuticals has announced the opening of a global manufacturing hub in Finland for the drug substance of its intravesical non-replicating gene therapy Adstiladrin (nadofaragene firadenovec-vncg). 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
The BioIndustry Association (BIA), in collaboration with the Centre for Process Innovation (CPI), has published a new report on the UK’s mRNA sector. 2 October 2024
Aspen Neuroscience, a private biotechnology company specializing in autologous cell therapies, has announced the opening of a major new facility near its headquarters in San Diego. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases.